Navigation Links
Study finds link between commonly prescribed statin and memory impairment
Date:9/25/2013

New research that looked at whether two commonly prescribed statin medicines, used to lower low-density lipoprotein (LDL) or 'bad cholesterol' levels in the blood, can adversely affect cognitive function has found that one of the drugs tested caused memory impairment in rats.

Between six and seven million people in the UK1 take statins daily and the findings follow anecdotal evidence of people reporting that they feel that their newly prescribed statin is affecting their memory. Last year, the US Food and Drug Administration (FDA) insisted that all manufacturers list in their side effects that statins might affect cognitive function.

The study, led by scientists at the University of Bristol and published in the journal PLOS ONE, tested pravastatin and atorvostatin (two commonly prescribed statins) in rat learning and memory models. The findings show that while no adverse cognitive effects were observed in rat performance for simple learning and memory tasks for atorvostatin, pravastatin impaired their performance.

Rats were treated daily with pravastatin (brand name - pravachol) or atorvostatin (brand name - Lipitor) for 18 days. The rodents were tested in a simple learning task before, during and after treatment, where they had to learn where to find a food reward. On the last day of treatment and following one week withdrawal, the rats were also tested in a task which measures their ability to recognise a previously encountered object (recognition memory).

The study's findings showed that pravastatin tended to impair learning over the last few days of treatment although this effect was fully reversed once treatment ceased. However, in the novel object discrimination task, pravastatin impaired object recognition memory. While no effects were observed for atorvostatin in either task.

The results suggest that chronic treatment with pravastatin impairs working and recognition memory in rodents. The reversibility of the effects on stopping treatment is similar to what has been observed in patients, but the lack of effect of atorvostatin suggests that some types of statin may be more likely to cause cognitive impairment than others.

Neil Marrion, Professor of Neuroscience at Bristol's School of Physiology and Pharmacology and the study's lead author, said: "This finding is novel and likely reflects both the anecdotal reports and FDA advice. What is most interesting is that it is not a feature of all statins. However, in order to better understand the relationship between statin treatment and cognitive function, further studies are needed."


'/>"/>

Contact: Caroline Clancy
caroline.clancy@bristol.ac.uk
44-011-792-88086
University of Bristol
Source:Eurekalert

Related medicine news :

1. Professors at Purchase College and Columbia University Receive More Than $500,000 in Grants to Study New Ways to Reduce Anxiety Disorders
2. Penn Medicine study: Proton therapy cuts side effects for pediatric head and neck cancer patients
3. Study: Majority of patients who qualify for lifesaving heart treatment do not receive it
4. Mayo-led study: Drug fails to reduce diarrhea in patients receiving radiation therapy
5. Loyola study assesses use of fingerstick blood sample with i-STAT point-of-care device
6. Brain may rely on computer-like mechanism to make sense of novel situations, says CU-Boulder study
7. CDC, MGH study reveals that preventing malaria in travelers to West Africa reduces health costs
8. Perfume Industry Review of Natural & Synthetic Perfumes for Global & China Markets in a New Research Study Available at DeepResearchReports.com
9. Stronger sexual impulses may explain why men cheat more than women, study reveals
10. Moffitt Cancer Center launches prostate cancer study focused on black men
11. School of Public Health Receives $390,000 Grant to Study Alcohol Use Among Youth Acquiring HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... 2016 , ... After a year and a half of planning the Multiple Pathways of ... Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic ... came together to explore the many pathways individuals use to get into and sustain their ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... ... , ... This campaign aims to provide a path to improved education and ... and change. , As nearly 795,000 Americans suffering from a new or recurrent stoke ... with an estimated 129,000 of these people dying from stroke, it’s become our nation’s ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the ... for an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center ... Market Committee (FOMC) dot charts are of interest to the press for their noise ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology: